3D ultrasound in neoadjuvant therapy of breast tumors
نویسندگان
چکیده
The iU22 is provided with the new VL13-5 3D linear array transducer (Figure 1). This transducer combines an easy-to-use ergonomic design with state-of-the-art imaging capabilities, including Tissue Aberration Correction (TAC). TAC is a new technology that corrects for the different speeds of sound associated with different tissue types, such as fat and glandular tissue in the breast, resulting in sharper images with better spatial resolution and less clutter.
منابع مشابه
Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
Background and objective:Breast cancer is the most common malignancy among women. The Neoadjuvant chemotherapy is the treatment of choice for non-operable tumors. The Ki67 is a proliferation marker that can be used to predict the therapeutic response to chemotherapy and the patients' prognosis. Methods: This retrospective study was carri...
متن کاملDissection axillary lymph node count in patient with breast cancer followed by neoadjuvant therapy
Introduction: Breast cancer is the most common cancer and the second cause of death in women. It is essential to have the highest level of confidence in axillary staging assessment. Many surgeons and pathologists believe that fewer lymph nodes are present in axillary dissection specimens of women treated by neoadjuvant chemotherapy. Consequently, the purpose of this study was to compare the lym...
متن کاملThe application of discriminant analysis in differentiation of fibroadenoma and ductal carcinoma of breast tissue using ultrasound velocity measurement
Background: Ultrasound propagation velocity was measured experimentally in normal, fibroadenoma and ductal carcinoma breast tissues, in order to distinguish normal breast tissue from tumors. Materials and methods: In quantitative measurements of ultrasound velocity, 403 breast tissue images were selected, comprising 130 normal breast tissue, 130 fibroadenoma, and 143 ductal carcinoma tumors. Th...
متن کاملNeoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial
BACKGROUND The response to neoadjuvant chemotherapy (NAC) varies by estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) statuses, with responses being lower in ER-positive, HER2-negative tumors as compared with ER-negative, HER2-positive or triple-negative tumors. Neoadjuvant endocrine therapy (NET) is an attractive alternative to NAC for ER-positive, HER2-negative cancer...
متن کاملNeoadjuvant therapy with gemcitabine in breast cancer.
Primary systemic therapy (ie, preoperative or neoadjuvant) increases the possibility for breast-conserving surgery in patients with primary breast cancer. Patients with pathologic complete response to primary systemic therapy have improved survival compared with those with persistent tumors. Several phase II trials have evaluated gemcitabine-containing doublet or triplet regimens as primary sys...
متن کامل